NEW YORK, August 3, 2026, 17:55 EDT
- Vertex increased its 2026 revenue outlook following stronger-than-expected second-quarter sales.
- Cystic-fibrosis drugs continued to account for 96% of revenue in the quarter.
- Casgevy and Journavx are required to generate no less than $302 million in the latter half.
Vertex Pharmaceuticals Incorporated NASDAQ:VRTX lifted its yearly sales forecast as cystic-fibrosis treatments fueled a 12% rise in quarterly revenue. Shares traded almost flat around $470 following hours, after a 1.3% drop to $470.72 at the close.
The projected growth continued to be driven primarily by cystic fibrosis. Vertex maintained its non-CF revenue goal at $500 million or above. This sets up a definitive challenge for the second half.
Casgevy and Journavx generated $197.9 million in revenue over the first six months. For the second half, they require at least $302.1 million, which is 52.7% higher than their first-half results, according to company data.
| Quarterly scorecard | Q2 2026 | Q2 2025 | Change | Analyst view |
|---|---|---|---|---|
| Revenue | $3.334 bln | $2.965 bln | +12.5% | $3.23 bln |
| Non-GAAP diluted EPS | $4.73 | $4.52 | +4.6% | In line |
| GAAP net income | $1.100 bln | $1.033 bln | +6.5% | — |
| U.S. revenue | $2.06 bln | — | +11% | — |
| International revenue | $1.28 bln | — | +14% | — |
Company data; analyst projections gathered by LSEG. Calculations for percentage changes are included.
Revenue surpassed the average analyst estimate by roughly 3.2%. Adjusted earnings were in line with projections. Increased spending on launches and investments in the renal franchise capped profit growth.
The improved forecast reflects the product mix. Alyftrek contributed $416.8 million in additional revenue year-on-year, while decreases in Trikafta and legacy CF products reduced that by just $110.5 million.
| Product revenue | Q2 2026 | Q2 2025 | Change | Growth |
|---|---|---|---|---|
| Trikafta/Kaftrio | $2,497.2 mln | $2,551.1 mln | -$53.9 mln | -2.1% |
| Alyftrek | $573.6 mln | $156.8 mln | +$416.8 mln | +265.8% |
| Other CF products | $137.1 mln | $193.7 mln | -$56.6 mln | -29.2% |
| Total CF products | $3,207.9 mln | $2,901.6 mln | +$306.3 mln | +10.6% |
| Casgevy | $76.4 mln | $30.4 mln | +$46.0 mln | +151.3% |
| Journavx | $49.6 mln | $12.0 mln | +$37.6 mln | +313.3% |
Company figures; changes have been computed.
CF medicines accounted for 96.2% of revenue for the quarter. They contributed roughly 83% of the company’s revenue growth compared to a year earlier. Diversification is progressing, though still limited.
Combined sales of Casgevy and Journavx totaled $126 million in the quarter, an increase of 75% over their joint first-quarter revenue. Despite the rise, the products accounted for just 3.8% of overall sales.
| Non-CF sales test | Amount |
|---|---|
| Casgevy revenue, first half | $119.3 mln |
| Journavx revenue, first half | $78.6 mln |
| Total revenue, first half | $197.9 mln |
| Annual company goal | At least $500.0 mln |
| Second-half revenue needed | At least $302.1 mln |
| Second-half growth needed compared to first half | At least 52.7% |
| Average per quarter needed in second half | At least $151.1 mln |
| Average per second-half quarter vs Q2 | At least 19.9% more |
Figures are based on company-stated first-half revenue.
The average quarterly revenue in the second half must surpass $151 million. This figure stands around 20% higher than the current pace. Sustained sequential growth is required to meet this target.
Vertex raised its annual forecast midpoint by $125 million, while leaving the non-CF floor and currency assumption unchanged. According to the stated assumptions, this indicates that the higher midpoint largely results from improved CF expectations.
| 2026 outlook | Current | Prior | Change |
|---|---|---|---|
| Total revenue | $13.10–$13.20 bln | $12.95–$13.10 bln | Midpoint +$125 mln |
| Non-CF revenue | No less than $500 mln | No less than $500 mln | Unchanged |
| Currency impact on growth | Approx. 150 basis points | Approx. 150 basis points | Unchanged |
| Non-GAAP R&D, acquired R&D and SG&A | $5.65–$5.75 bln | $5.65–$5.75 bln | Unchanged |
| Non-GAAP tax rate | 19.5%–20.5% | 19.5%–20.5% | Unchanged |
Vertex CEO Reshma Kewalramani stated the company was “expanding our leadership in cystic fibrosis.” She highlighted advances in blood disorders and acute pain. Business Wire
Vertex aims to acquire Crinetics Pharmaceuticals NASDAQ:CRNX, securing treatments for rare endocrine disorders. The deal is valued at $10 billion, with an adjusted figure of $8.8 billion after estimated cash on hand is deducted. The closing is targeted for the third quarter.
Vertex has not included the agreement in its existing outlook. The company intends to finance the transaction with a combination of cash and debt, backed by $4.5 billion in bridge financing. Guidance will be revised by management once the transaction is finalized.
| Profitable biotechnology peer review | Share price | Daily move | Market value | Trailing P/E |
|---|---|---|---|---|
| Vertex NASDAQ:VRTX | $470.72 | -1.3% | $120.6 bln | 27.9x |
| Regeneron Pharmaceuticals NASDAQ:REGN | $759.24 | -0.4% | $80.5 bln | 18.8x |
| Gilead Sciences NASDAQ:GILD | $131.15 | +0.7% | $164.5 bln | 17.8x |
| Alnylam Pharmaceuticals NASDAQ:ALNY | $220.33 | +7.2% | $30.5 bln | 38.4x |
Data on prices and valuation are from Monday’s trading session.
Vertex trades at an earnings multiple roughly 52% higher than the Regeneron-Gilead average. This premium raises expectations for both successful product launches and expansion of the company’s pipeline.
The stock showed little movement last week, closing Friday at $477.10 compared to $477.36 the previous week. After Monday’s drop, it was 11.8% beneath its July 7 intraday peak.
Tuesday marks the first opportunity for a full-day market reaction to the results. Upcoming events to watch are the Crinetics deal close and the November 30 FDA ruling on the kidney therapy povetacicept.
Risks: Casgevy and Journavx could fail to achieve the necessary momentum in the second half. There is potential for softer CF demand or pricing. The Crinetics deal adds risks related to funding, regulation, and integration.
Related articles: NASDAQ:VRTX
